Cell Signaling Technology

Product Pathways - Development

Jagged1 (28H8) Rabbit mAb #2620

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP H M (R) Endogenous 180 Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Jagged1 (28H8) Rabbit mAb detects endogenous levels of total Jagged1 protein. It does not cross-react with Jagged2.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu1140 (intracellular region) of human Jagged1.

Western Blotting

Western Blotting

Western blot analysis of total cell lysates from HepG2 and LNCaP cells, using Jagged1 (28H8) Rabbit mAb.

Background

Notch signaling is activated upon engagement of the Notch receptor with its ligands, the DSL (Delta, Serrate, Lag2) proteins of single-pass type I membrane proteins. The DSL proteins contain multiple EGF-like repeats and a DSL domain that is required for binding to Notch (1,2). Five DSL proteins have been identified in mammals: Jagged1, Jagged2, Delta-like (DLL) 1, 3 and 4 (3). Ligand binding to the Notch receptor results in two sequential proteolytic cleavages of the receptor by the ADAM protease and the γ-secretase complex. The intracellular domain of Notch is released and then translocates to the nucleus where it activates transcription. Notch ligands may also be processed in a way similiar to Notch, suggesting a bi-directional signaling through receptor-ligand interactions (4-6).

Mutation in Jagged1 is associated with Alagille syndrome, an autosomal dominant disorder characterized by abnormal development of liver, heart, skeleton, eye, and face (7, 8) and Tetralogy of Fallot (ToF), a common form of complex congenital heart disease (9). Jagged1 expression is associated with prostate cancer metastasis and recurrence (10).

  1. Wilson, A. and Radtke, F. (2006) FEBS Lett. 580, 2860-2868.
  2. Hansson, E.M. et al. (2004) Semin. Cancer Biol. 14, 320-328.
  3. Chiba, S. (2006) Stem Cells 24, 2437-2447.
  4. Bland, C.E. et al. (2003) J. Biol. Chem. 278, 13607-13610.
  5. Six, E. et al. (2003) Proc. Natl. Acad. Sci. USA 100, 7638-7643.
  6. LaVoie, M.J. and Selkoe, D.J. (2003) J. Biol. Chem. 278, 34427-34437.
  7. Li, L. et al. (1997) Nat. Genet. 16, 243-251.
  8. Röpke, A. et al. (2003) Hum. Mutat. 21, 100.
  9. Eldadah, Z.A. et al. (2001) Hum. Mol. Genet. 10, 163-169.
  10. Santagata, S. et al. (2004) Cancer Res 64, 6854-6857.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Rabbit Monoclonals Produced Using Epitomics® Technology, U.S. Patent No. 5,675,063.

For Research Use Only. Not For Use In Diagnostic Procedures.

Products